AstraZeneca joins Boehringer Ingelheim in capping out-of-pocket inhaler costs at $35
18 Mar 2024
Biosimilar
Just as insulin manufacturers were pressured into capping monthly out-of-pocket costs, inhaler manufacturers are feeling the same heat. AstraZeneca on Monday joined with Boehringer Ingelheim to cap the price of its blockbuster inhalers at $35 per month.
Beginning on June 1, AstraZeneca’s four inhalers, including Symbicort and Airsupra, will be capped, according to the company. AstraZeneca recorded more than $2.3 billion in Symbicort sales in 2023, but generic competition entered the US market in the third quarter of last year.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.